Back HIV/AIDS

HIV / AIDS

IAS 2015: Many People with Long-term HIV Infection Do Not Achieve Full CD4 Cell Recovery

One-third of people who started combination antiretroviral therapy (ART) many years ago using first-generation protease inhibitors did not achieve complete immunological recovery with normal CD4 T-cell counts despite good viral suppression, according to a French study presented at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention in Vancouver.

alt

IAS 2015: Gay Men Are Using Nuanced Sero-adaptive Behaviors to Prevent HIV Infection

There is evidence that some groups of Australian and American gay men are considering HIV-positive partners’ undetectable viral load and the time elapsed since an HIV-negative partner last tested when making decisions about using condoms, according to studies presented at the recent 8th International AIDS Society Conference in Vancouver.

alt

IAS 2015: Peer or Community Interventions Improve Outcomes for Mothers with HIV

Peer- and community-based interventions can significantly increase retention in care of mothers with HIV and improve attendance at early prenatal clinic visits, according to results from 2 large multi-country studies presented last month at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) in Vancouver.

alt

IAS 2015: PrEP Adherence, Sexual Behavior, and HIV and STI Incidence [VIDEO]

An open-label Truvada pre-exposure prophylaxis (PrEP) demonstration project, which included more than 500 mostly gay and bisexual men in San Francisco, Miami, and Washington, DC, showed that adherence was generally good overall -- especially among people at highest risk for HIV infection -- but there were some important disparities, researchers reported at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention in Vancouver.

alt

IAS 2015: HIV+ People with Asymptomatic Cognitive Impairment More Likely to Develop Symptoms

People with HIV who showed evidence of asymptomatic neurocognitive impairment at study entry were nearly twice as likely to progress to symptomatic HIV-associated neurocognitive disorders than those with initially normal neuropsychological tests, according to research presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver.

alt

Tenofovir Alafenamide Combo Pill Matches Truvada for HIV Efficacy, but Easier on Bones and Kidneys

A fixed-dose combination pill containing tenofovir alafenamide (TAF) worked as well in a Phase 3 trial as the current Truvada pill containing the older tenofovir disoproxil fumarate (TDF) -- which is used for both HIV treatment and pre-exposure prophylaxis or PrEP -- but causes less kidney and bone toxicity, according to an announcement this week from Gilead Sciences.

alt

IAS 2015: Estrogen May Block HIV Reactivation, Hints at Gender Differences in Viral Reservoirs

Estrogen receptors on cells may play a role in HIV latency and reactivation, and drugs targeting these receptors could potentially be used to either promote reactivation of integrated viral genes or keep them silent, according to research presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention and at the preceding IAS Towards an HIV Cure Symposium last month in Vancouver.

alt